enGene Therapeutics Inc. (ENGN)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
EnGene Therapeutics: The Selloff Creates An Opportunity
enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data for its sole asset, detalimogene voraplasmid. ENGN's therapy showed only a 25% 12-month complete response rate, underperforming competitors, but boasts a strong safety profile and Fast Track/RMAT status. Risks include FDA rejection and insurers declining coverage due to low efficacy, but current valuation implies limited further downside given the cash position.
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
enGene NASDAQ: ENGN reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
enGene Holdings: Key Catalysts Incoming For 2026
enGene Holdings remains on track with a cautiously optimistic 'Buy' rating, supported by promising clinical data and strong financial positioning. ENGN's lead candidate, detalimogene voraplasmid, demonstrated a 63% complete response rate at 3 months in NMIBC, with favorable tolerability and pivotal cohort enrollment exceeding targets. ENGN plans a pivotal LEGEND cohort update at a spring 2026 medical conference, with a BLA submission for FDA approval anticipated in the second half of 2026.
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
enGene: Two Major Catalysts On Deck For 2nd Half Of 2026
enGene Holdings (ENGN) maintains a Buy rating, driven by positive preliminary data and two major catalysts expected in 2H 2026. ENGN's detalimogene gene therapy achieved a 62% 6-month complete response rate in BCG-unresponsive, high-risk NMIBC with CIS post-amendment. ENGN is positioned as a potential first-line, best-in-class option for BCG-unresponsive NMIBC, offering ease of use and strong tolerability.
enGene Holdings: Still A Buy After A Massive Surge
enGene Holdings remains a Buy, driven by promising LEGEND trial data for detalimogene voraplasmid in non-muscle invasive bladder cancer. ENGN's phase 2 LEGEND trial showed a 63% complete response rate, comparable to ImmunityBio's Anktiva, positioning ENGN as a strong NMIBC contender. ENGN has a robust cash runway into 2027, supporting continued operations and potential approval without immediate fundraising concerns.
enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript
enGene Holdings Inc. ( ENGN ) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC November 11, 2025 8:00 AM EST Company Participants Lauren Hopfer Ronald H. Cooper - President, CEO & Director Hussein Sweiti - Chief Medical Officer Conference Call Participants Suzanne Merrill Yanan Zhu - Wells Fargo Securities, LLC, Research Division Judah Frommer - Morgan Stanley, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Andres Maldonado - H.C.
EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
enGene Holdings Inc. (NASDAQ:ENGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Ronald H. Cooper - President, CEO & Director Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Welcome to the session of the Morgan Stanley Global Healthcare Conference.
enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)
enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, ENGN maintains a cash runway into 2027, supporting ongoing development without major liquidity concerns in the near term. While regulatory discussions are encouraging, the investment thesis hinges on positive LEGEND trial results, making this a high-risk, high-reward scenario.
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch
enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene voraplasmid, enGene's lead asset, shows high complete response rates in BCG-unresponsive NMIBC patients, positioning it as a viable monotherapy option. Financials reveal a market cap of $320mn and a cash runway of 14–17 quarters, indicating undervaluation compared to market potential.
Best Momentum Stocks to Buy for February 19th
NVMI, FRSH and ENGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 19, 2024.
